Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Toxins (Basel) ; 13(5)2021 05 17.
Artículo en Inglés | MEDLINE | ID: mdl-34067828

RESUMEN

The primary studies have shown that scorpion analgesic peptide N58A has a significant effect on voltage-gated sodium channels (VGSCs) and plays an important role in neuropathic pain. The purpose of this study was to investigate the analgesic effect of N58A on trigeminal neuralgia (TN) and its possible mechanism. The results showed that N58A could significantly increase the threshold of mechanical pain and thermal pain and inhibit the spontaneous asymmetric scratching behavior of rats. Western blotting results showed that N58A could significantly reduce the protein phosphorylation level of ERK1/2, P38, JNK, and ERK5/CREB pathways and the expression of Nav1.8 and Nav1.9 proteins in a dose-dependent manner. The changes in current and kinetic characteristics of Nav1.8 and Nav1.9 channels in TG neurons were detected by the whole-cell patch clamp technique. The results showed that N58A significantly decreased the current density of Nav1.8 and Nav1.9 in model rats, and shifted the activation curve to hyperpolarization and the inactivation curve to depolarization. In conclusion, the analgesic effect of N58A on the chronic constriction injury of the infraorbital (IoN-CCI) model rats may be closely related to the regulation of the MAPK pathway and Nav1.8 and Nav1.9 sodium channels.


Asunto(s)
Analgésicos/farmacología , Péptidos/farmacología , Venenos de Escorpión/química , Neuralgia del Trigémino/tratamiento farmacológico , Analgésicos/administración & dosificación , Analgésicos/aislamiento & purificación , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.8/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.8/metabolismo , Canal de Sodio Activado por Voltaje NAV1.9/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.9/metabolismo , Dolor/tratamiento farmacológico , Técnicas de Placa-Clamp , Péptidos/administración & dosificación , Péptidos/aislamiento & purificación , Ratas , Ratas Sprague-Dawley , Escorpiones , Tetrodotoxina/farmacología
3.
Biomed Pharmacother ; 106: 930-940, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30119265

RESUMEN

BACKGROUND: Oxaliplatin-induced cold allodynia is a frequent complication appearing in patients treated with this anti-tumor drug. Since, there are no clear algorithms to overcome this painful condition effectively, it is important to establish novel strategies for its treatment. AIM: In this study, the ability of pregabalin and ambroxol, used as single drugs or in combinations administered in a time-shifted manner to attenuate cold allodynia was assessed in the mouse cold plate test. The hot plate test was additionally used to assess antinociceptive properties of ambroxol in the acute, thermally-induced pain model. Locomotor activity and motor coordination of mice were also evaluated. In silico studies were undertaken to predict potential binding of ambroxol to sodium channel (Nav) subtypes whose overexpression is implicated in the development of oxaliplatin-induced neuropathic pain. KEY FINDINGS: A hyperadditive antiallodynic effect of combined sub-analgesic ambroxol and pregabalin was demonstrated in oxaliplatin-treated mice. This effect was particularly strong when these drugs were given 4 h apart. Both drugs used in combination reduced animals' locomotor activity, but they did not impair motor coordination in the rotarod test. Ambroxol did not show antinociceptive properties in the hot plate test. The molecular docking studies predicted that in mice ambroxol might bind to Nav1.6 and Nav1.9 rather than Nav1.7 and Nav1.8. SIGNIFICANCE: Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin effectively attenuates oxaliplatin-induced cold allodynia. Molecular docking model predicts preferential binding of ambroxol to mouse Nav1.6, Nav1.9 channels. This mechanism, if confirmed in vitro, might explain pharmacological activities observed in vivo.


Asunto(s)
Ambroxol/administración & dosificación , Analgésicos/administración & dosificación , Frío , Hiperalgesia/prevención & control , Canal de Sodio Activado por Voltaje NAV1.6/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.9/efectos de los fármacos , Oxaliplatino , Umbral del Dolor/efectos de los fármacos , Pregabalina/administración & dosificación , Ambroxol/metabolismo , Analgésicos/metabolismo , Animales , Conducta Animal/efectos de los fármacos , Sitios de Unión , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Quimioterapia Combinada , Hiperalgesia/inducido químicamente , Hiperalgesia/metabolismo , Hiperalgesia/fisiopatología , Masculino , Ratones , Simulación del Acoplamiento Molecular , Actividad Motora/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.6/metabolismo , Canal de Sodio Activado por Voltaje NAV1.9/metabolismo , Unión Proteica , Prueba de Desempeño de Rotación con Aceleración Constante , Transducción de Señal/efectos de los fármacos , Factores de Tiempo
4.
Mar Drugs ; 15(9)2017 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-28867800

RESUMEN

Ciguatoxins (CTXs) are marine toxins that cause ciguatera fish poisoning, a debilitating disease dominated by sensory and neurological disturbances that include cold allodynia and various painful symptoms as well as long-lasting pruritus. Although CTXs are known as the most potent mammalian sodium channel activator toxins, the etiology of many of its neurosensory symptoms remains unresolved. We recently described that local application of 1 nM Pacific Ciguatoxin-1 (P-CTX-1) into the skin of human subjects induces a long-lasting, painful axon reflex flare and that CTXs are particularly effective in releasing calcitonin-gene related peptide (CGRP) from nerve terminals. In this study, we used mouse and rat skin preparations and enzyme-linked immunosorbent assays (ELISA) to study the molecular mechanism by which P-CTX-1 induces CGRP release. We show that P-CTX-1 induces CGRP release more effectively in mouse as compared to rat skin, exhibiting EC50 concentrations in the low nanomolar range. P-CTX-1-induced CGRP release from skin is dependent on extracellular calcium and sodium, but independent from the activation of various thermosensory transient receptor potential (TRP) ion channels. In contrast, lidocaine and tetrodotoxin (TTX) reduce CGRP release by 53-75%, with the remaining fraction involving L-type and T-type voltage-gated calcium channels (VGCC). Using transgenic mice, we revealed that the TTX-resistant voltage-gated sodium channel (VGSC) NaV1.9, but not NaV1.8 or NaV1.7 alone and the combined activation of the TTX-sensitive VGSC subtypes NaV1.7 and NaV1.1 carry the largest part of the P-CTX-1-caused CGRP release of 42% and 34%, respectively. Given the contribution of CGRP to nociceptive and itch sensing pathways, our findings contribute to a better understanding of sensory symptoms of acute and chronic ciguatera that may help in the identification of potential therapeutics.


Asunto(s)
Ciguatoxinas/farmacología , Canal de Sodio Activado por Voltaje NAV1.1/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.7/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.9/efectos de los fármacos , Receptores de Péptido Relacionado con el Gen de Calcitonina/efectos de los fármacos , Animales , Péptido Relacionado con Gen de Calcitonina/efectos de los fármacos , Calcio/metabolismo , Intoxicación por Ciguatera/metabolismo , Ciguatoxinas/química , Ensayo de Inmunoadsorción Enzimática , Humanos , Hiperalgesia/inducido químicamente , Lidocaína/farmacología , Masculino , Toxinas Marinas/farmacología , Potenciales de la Membrana/efectos de los fármacos , Ratones , Ratones Transgénicos , Ratas , Tetrodotoxina/farmacología
5.
Lung ; 192(1): 15-20, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24272479

RESUMEN

Recent advances in our understanding of voltage-gated sodium channels (NaVs) lead to the rational hypothesis that drugs capable of selective blockade of NaV subtypes may be a safe and effective strategy for the treatment of unwanted cough. Among the nine NaV subtypes (NaV1.1-NaV1.9), the afferent nerves involved in initiating cough, in common with nociceptive neurons in the somatosensory system, express mainly NaV1.7, NaV1.8, and NaV1.9. Although knowledge about the effect of selectively blocking these channels on the cough reflex is limited, their biophysical properties indicate that each may contribute to the hypertussive and allotussive state that typifies subacute and chronic nonproductive cough.


Asunto(s)
Antitusígenos/uso terapéutico , Tos/tratamiento farmacológico , Canal de Sodio Activado por Voltaje NAV1.7/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.8/efectos de los fármacos , Neuronas Aferentes/efectos de los fármacos , Reflejo/efectos de los fármacos , Bloqueadores de los Canales de Sodio/uso terapéutico , Animales , Antitusígenos/efectos adversos , Tos/metabolismo , Tos/fisiopatología , Diseño de Fármacos , Humanos , Terapia Molecular Dirigida , Canal de Sodio Activado por Voltaje NAV1.7/metabolismo , Canal de Sodio Activado por Voltaje NAV1.8/metabolismo , Canal de Sodio Activado por Voltaje NAV1.9/efectos de los fármacos , Canal de Sodio Activado por Voltaje NAV1.9/metabolismo , Neuronas Aferentes/metabolismo , Bloqueadores de los Canales de Sodio/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA